Adekunle Muiz Mofolorunso
Adekunle Muiz Mofolorunso has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adegbesan Bukunola Oluyemisi
Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Ogun State, Nigeria
1 shared publication - Esther Nkechi Ezima
Sagamu Campus, Olabisi Onabanjo University, Ago-Iwoye, OgunState, Nigeria
1 shared publication - Gideon Olamilekan Oluwatunase1 shared publication
- Gideon Olamilekan Oluwatunase
Department of Anatomy, University of Medical Sciences, Ondo state, Nigeria; Department of Anatomy, Olabisi Onabanjo University, Ago-Iwoye, Ogun state, Nigeria
1 shared publication - Ifabunmi Oduyemi Osonuga
(1) Department of Physiology, Faculty of Basic Medical Sciences, Olabisi Onabanjo University, Sagamu Campus, Sagamu, Ogun State, Nigeria
1 shared publication Olayinka Olawale Asafa
1 shared publication
Latest Publications
- Open Access
- 3 June 2025
- Published by IntechOpen
Gut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.
- 3 June 2025
- Published by IntechOpen
Open AccessGut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.
- Open Access
- 1 February 2024
- Published by IntechOpen
The Complex Interplay: Unfolding the Mechanisms of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a widely prevalent respiratory ailment that can be prevented. It is characterized by the chronic restriction of airflow caused by lung abnormalities resulting from exposure to toxic chemicals or particles. COPD is a respiratory disorder characterized by a gradual and incapacitating progression, impacting a significant number of individuals on a global scale. COPD is distinguished by the presence of chronic bronchitis and emphysema, resulting in considerable morbidity and mortality. The etiology of COPD is multifaceted, encompassing genetic, environmental, and physiological variables. In spite of the existence of global health objectives, the incidence and mortality rates of COPD persistently escalate, exhibiting disparities influenced by factors such as gender, geographical location, and age. The increasing prevalence of COPD, therefore, necessitates a pressing requirement for enhancing treatment approaches and patient outcomes.
- 1 February 2024
- Published by IntechOpen
Open AccessThe Complex Interplay: Unfolding the Mechanisms of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a widely prevalent respiratory ailment that can be prevented. It is characterized by the chronic restriction of airflow caused by lung abnormalities resulting from exposure to toxic chemicals or particles. COPD is a respiratory disorder characterized by a gradual and incapacitating progression, impacting a significant number of individuals on a global scale. COPD is distinguished by the presence of chronic bronchitis and emphysema, resulting in considerable morbidity and mortality. The etiology of COPD is multifaceted, encompassing genetic, environmental, and physiological variables. In spite of the existence of global health objectives, the incidence and mortality rates of COPD persistently escalate, exhibiting disparities influenced by factors such as gender, geographical location, and age. The increasing prevalence of COPD, therefore, necessitates a pressing requirement for enhancing treatment approaches and patient outcomes.